Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares stood at 1.76 million during the last session, with the company’s beta value hitting 0.98. At the close of trading, the stock’s price was $2.06, to imply an increase of 0.49% or $0.01 in intraday trading. The ESPR share’s 52-week high remains $3.40, putting it -65.05% down since that peak but still an impressive 65.53% since price per share fell to its 52-week low of $0.71. The company has a valuation of $404.21M, with an average of 2.67 million shares in intraday trading volume over the past 10 days and average of 3.68 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Esperion Therapeutics Inc. (ESPR), translating to a mean rating of 1.71. Of 8 analyst(s) looking at the stock, 0 analyst(s) give ESPR a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
After registering a 0.49% upside in the last session, Esperion Therapeutics Inc. (ESPR) has traded red over the past five days. The 5-day price performance for the stock is -2.37%, and 27.95% over 30 days. With these gigs, the year-to-date price performance is -31.10%. Short interest in Esperion Therapeutics Inc. (NASDAQ:ESPR) saw shorts transact 37.47 million shares and set a 12.69 days time to cover.
The extremes give us $12 and $20 for target low and target high price respectively. As such, ESPR has been trading -870.87% off suggested target high and -482.52% from its likely low.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Looking at statistics comparing Esperion Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Esperion Therapeutics Inc. (ESPR) shares are 3.52% up over the last 6 months, with its year-to-date growth rate higher than industry average at 98.03% against 17.60%. Revenue is forecast to grow 54.10% this quarter before jumping 86.00% for the next one. The rating firms project that company’s revenue will grow 194.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 52.38M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 60.52M.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 23.09% for the past 5-year period. While 2024 is set for a 85.83% return in earnings, projections for the next 5 years are at 16.90% annually.
ESPR Dividends
Esperion Therapeutics Inc. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
Esperion Therapeutics Inc. insiders hold 0.50% of total outstanding shares, with institutional holders owning 68.69% of the shares at 69.04% float percentage. In total, 68.69% institutions holds shares in the company, led by WASATCH ADVISORS LP. As of 2024-06-30, the company held over 16.86 million shares (or 9.9628% of shares), all amounting to roughly $37.44 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 13.98 million shares, or about 8.2617% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $31.04 million.
